PaxVax submits IND for refurbished Crucell one-dose oral cholera vaccine
This article was originally published in Scrip
Executive Summary
PaxVax Corp. took a step forward in its commercial and social missions to develop innovative vaccines against infectious diseases with the US FDA's acceptance of the company's investigational new drug (IND) application for its single-dose, oral cholera vaccine.